We are live on ! Find out more
NVO

Novo Nordisk

640 hedge funds and large institutions have $9.9B invested in Novo Nordisk in 2019 Q4 according to their latest regulatory filings, with 119 funds opening new positions, 182 increasing their positions, 221 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

261% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 33

216% more call options, than puts

Call options by funds: $94.7M | Put options by funds: $30M

44% more funds holding in top 10

Funds holding in top 10: 913 (+4)

13% more funds holding

Funds holding: 564640 (+76)

12% more capital invested

Capital invested by funds: $8.88B → $9.9B (+$1.02B)

0.16% less ownership

Funds ownership: 18.53%18.37% (-0.16%)

18% less repeat investments, than reductions

Existing positions increased: 182 | Existing positions reduced: 221

Holders
640
Holders Change
+76
Holders Change %
+13.48%
% of All Funds
12.61%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.26%
New
119
Increased
182
Reduced
221
Closed
33
Calls
$94.7M
Puts
$30M
Net Calls
+$64.7M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Russell Investments Group
51
Russell Investments Group
United Kingdom
$25.3M -$1.32M -47,538 -5%
AIA
52
Avalon Investment & Advisory
Texas
$24.5M -$23.5K -850 -0.1%
QI
53
QV Investors
Alberta, Canada
$23M +$3.17M +114,640 +17%
PFM
54
Parsec Financial Management
North Carolina
$22.4M -$533K -19,248 -2%
BCPEMI
55
Bain Capital Public Equity Management II
Massachusetts
$20.8M +$19.9M +719,148 New
BIAS
56
Beacon Investment Advisory Services
New Jersey
$19.4M +$17.7M +638,650 +1,971%
O
57
OrbiMed
New York
$19.1M
Stifel Financial
58
Stifel Financial
Missouri
$18.1M +$1.68M +60,510 +11%
Franklin Resources
59
Franklin Resources
California
$17.9M -$1.69M -61,170 -9%
SI
60
Scout Investments
Missouri
$17.5M -$417K -15,050 -2%
GHA
61
GW Henssler & Associates
Georgia
$17.3M +$936K +33,800 +6%
NPA
62
Nichols & Pratt Advisers
Massachusetts
$15.3M -$114K -4,130 -0.8%
Citadel Advisors
63
Citadel Advisors
Florida
$14.2M -$1.72M -62,034 -11%
OAM
64
Oppenheimer Asset Management
New York
$13.3M +$509K +18,374 +4%
Voloridge Investment Management
65
Voloridge Investment Management
Florida
$13M +$7.63M +275,606 +159%
Bank of Montreal
66
Bank of Montreal
Ontario, Canada
$12.9M +$951K +34,350 +8%
CL
67
CIM LLC
New York
$12.9M +$1.29M +46,620 +12%
TCM
68
Tekla Capital Management
Massachusetts
$12.8M -$1.09M -39,272 -8%
Janus Henderson Group
69
Janus Henderson Group
United Kingdom
$12.6M -$1.34M -48,396 -10%
CBT
70
Capital Bank & Trust
California
$12.5M -$1.66K -60 -0%
GC
71
Grimes & Company
Massachusetts
$12.1M -$268K -9,686 -2%
HCM
72
Hutchinson Capital Management
California
$11.2M -$71.8K -2,592 -0.7%
CTA
73
Carillon Tower Advisers
Florida
$11.2M -$417K -15,050 -4%
DJSG
74
D.J. St. Germain
Massachusetts
$11.1M -$56.9K -2,056 -0.5%
US Bancorp
75
US Bancorp
Minnesota
$11M -$660K -23,850 -6%

NVO Hedge Fund Activity: Q4 2019 in Review

640 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2019, worth a combined $9.9B — up 12% from $8.88B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new NVO positions and 33 closed out — a net gain of 86 holders — while 182 added to existing stakes and 221 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $79.2M. The largest seller was BlackRock, cutting an estimated $192M.

  • 640 institutional investors held Novo Nordisk (NVO) as of Q4 2019, up from 564 in Q3 2019.
  • Funds reported $9.9B of Novo Nordisk stock for Q4 2019, up 12% quarter-over-quarter.
  • 119 funds opened new Novo Nordisk positions in Q4 2019 and 33 closed out, a net change of +86 holders.
  • The largest Novo Nordisk buyer in Q4 2019 was Renaissance Technologies, an estimated $79.2M added.
  • The largest Novo Nordisk seller in Q4 2019 was BlackRock, an estimated $192M sold.

Based on aggregated 13F filings for Q4 2019.